article
Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema The Pan-American Collaborative Retina Study Group Results
Registro en:
ISSN: 1549-4713
EISSN: 0161-6420
Autor
Arevalo, J. Fernando
Maia, Mauricio
Garcia-Amaris, Rafael A.
Roca, Jose A.
Sanchez, Juan G.
Berrocal, Maria H.
Wu, Lihteh
Institución
Resumen
Objective: To determine the feasibility, safety, and clinical effect of intravitreal (IVT) bevacizumab (Avastin; Genentech, Inc., San Francisco, CA) in patients with refractory cystoid macular edema (CME) after cataract surgery. Design: Interventional, retrospective, multicenter study.